Stephanie N Robertson

US Patent:

6924117, Aug 2, 2005

Filed:

Jul 18, 2001

Appl. No.:

09/908419

Inventors:

Mario N. Lioubin - San Mateo CA, US
Lori Friedman - San Francisco CA, US
Marcia Belvin - Berkeley CA, US
Jeffery S. Larson - Burlingame CA, US
Changyou Chen - Castro Valley CA, US
Stephanie A. Robertson - San Francisco CA, US
Wen Shi - San Francisco CA, US
Jocelyn Chan - San Francisco CA, US
Danxi Li - San Francisco CA, US

Assignee:

Exelixis, Inc. - South San Francisco CA

International Classification:

C12Q001/68
A61K039/395
A01N037/18

US Classification:

435 723, 4241301, 4241781, 424 941, 514 2

Abstract:

Rhomboid Related Proteins (RRPs), involved in the EGFR signaling pathway, are provided. Transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide or a gene effecting the expression of an RRP polypeptide, along with methods of modulating the interaction of RRP proteins with their pathway members, and methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, such as RRP-specific antibodies and small molecules identified in high throughput screens, are also provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein.

US Patent:

20030165497, Sep 4, 2003

Filed:

Jan 23, 2002

Appl. No.:

10/056790

Inventors:

Mario Lioubin - San Mateo CA, US
Lori Friedman - San Francisco CA, US
Marcia Belvin - Albany CA, US
Jeffrey Larson - Burlingame CA, US
Changyou Chen - Castro Valley CA, US
Stephanie Robertson - San Francisco CA, US
Wen Shi - San Francisco CA, US
Jocelyn Chan - San Francisco CA, US
Danxi Li - San Francisco CA, US
Helen Francis-Lang - San Francisco CA, US
Gregory Plowman - San Carlos CA, US
Roel Funke - South San Francisco CA, US
Michael Schoor - Leverkusen, DE
Branko Zevnik - Leverkusen, DE
Gunther Kauselmann - Koeln, DE
Hartmut Tintrup - Cologne, DE

International Classification:

G01N033/574
A61K039/395

US Classification:

424/141100, 424/146100, 424/155100, 435/007230

Abstract:

RRP genes are identified as modulators of the p53 or p21 pathway, and thus are therapeutic targets for disorders associated with defective p53 or p21 function. Methods for identifying modulators of p53 or p21, comprising screening for agents that modulate the activity of RRP are provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. mRRP1 knockout mice are also provided.